ReviewFrontiers in cellular and infection microbiology2026
Research progress on the mechanisms of mucus retention after mycoplasma pneumoniae infection.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chlamydia trachomatis Pneumonia in a 50-Day-Old Full-Term Male Infant Associated With Mucus Plugging of the Left Upper Lobe Bronchus and Left Upper Lobe Atelectasis.The American journal of case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae (MP) is a significant pathogen causing community-acquired pneumonia (CAP) in children, often complicated by bronchial mucus plugs (BMPs), which can lead to atelectasis, respiratory failure, and other severe outcomes. This narrative review comprehensively discusses the molecular and cellular mechanisms underlying mucus retention post-MP infection, focusing on pathogen-host interactions, cytokine release, and activation of inflammatory signaling pathways that drive abnormal physicochemical changes in mucus. MP adheres to respiratory epithelial cells, inducing oxidative stress and cellular damage, while activating pathways such as NF-κB and MAPK to promote excessive mucin production. The host immune-inflammatory response-including neutrophil extracellular trap formation, Th1/Th2 imbalance, and release of cytokines like IL-4, IL-13, and TNF-α-further exacerbates mucus hypersecretion. Concurrently, physicochemical alterations in mucus combined with impaired ciliary clearance facilitate the transition of mucus from a sol to a gel state, ultimately causing mucus retention. The review also summarizes targeted therapeutic strategies, including macrolides, mucolytics, anti-inflammatory agents, traditional Chinese medicine (TCM) Therapies, and bronchoscopic interventions, to inform clinical management. Future research should prioritize elucidating drug-resistant mechanisms in macrolide-resistant mycoplasma pneumoniae (MRMP) and developing precision therapies to improve patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.